Kangmei Pharma | 600518 - Ebitda


Kangmei Pharma reported CNY-12.72M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Avita Medical AUD -5.56M 4.13M Jun/2026
Cspc Pharmaceutical CNY 2.19B 21.88M Dec/2024
Dianthus Therapeutics USD -61.38M 14.92M Jun/2026
Genomma Lab Internacional MXN 944.9M 31.44M Sep/2026
Hypermarcas BRL 782.25M 5.53M Sep/2026
Ionis Pharmaceuticals USD -95.22M 9.99M Sep/2026
IQVIA Holdings USD 1.03B 38M Sep/2026
Jiangsu Hengrui CNY 2.78B 379.11M Sep/2026
Kangmei Pharma CNY -12.72M 30.02M Mar/2026
Moderna USD -687M 571M Jun/2026
Organon & Co USD 502M 131M Sep/2026
Revvity USD 227.55M 629K Sep/2026
Sh Fosun Pharma CNY 1.61B 47.58M Sep/2026
Tectonic Therapeutic USD -21.18M 365K Dec/2025
Viatris USD 1.2B 7.4M Sep/2026
WuXi AppTec CNY 10.59B 2.61B Sep/2026
Xeris Pharmaceuticals USD -20.94M 33.27M Jun/2026
Zhangzhou Pientzehuang Pharmaceutical CNY 419.24M 463.46M Jun/2026